Identification and initial structure-activity relationships of (R)-5- (2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 407-412

  Holladay, Mark W ^a,b   Wasicak, James T ^a   Lin, Nan Horng ^a   He, Yun ^a   Ryther, Keith ^a   Bannon, Anthony W ^a   Buckley, Michael J ^a   Kim, David J B ^a   Decker, Michael W ^a   Anderson, David J ^a   Campbell, Jeffrey E ^a   Kuntzweiler, Theresa A ^a   Donnelly Roberts, Diana L ^a   Piattoni Kaplan, Marietta ^a   Briggs, Clark A ^a   Williams, Michael ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

^b AP10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ACETYLCHOLINE; ANALGESIC AGENT; AZETIDINE DERIVATIVE; CYTISINE; EPIBATIDINE; NICOTINE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; RUBIDIUM 86; TRITIUM; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DRUG POTENCY; ENANTIOMER; HOT PLATE TEST; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; WRITHING TEST;

ADMINISTRATION, ORAL; ANALGESICS, NON-NARCOTIC; ANIMALS; AZETIDINES; DIASTOLE; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; KINETICS; MICE; MOLECULAR STRUCTURE; MUSCLE CONTRACTION; NEUROBLASTOMA; NEURONS; NICOTINIC AGONISTS; OOCYTES; PAIN; PAIN MEASUREMENT; PYRIDINES; RATS; RECEPTORS, NICOTINIC; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOPUS;

EID: 14444277023     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9706224     Document Type: Article

References (31)

1. Spande, T. F.; Garaffo, H. M.; Edwards, M. W.; Yeh, H. J. C.; Pannell, L.; Daly, J. W. Epibatidine: A Novel (Chloropyridyl)-azabicycloheptane with Potent Analgesic Activity from an Ecuadoran Poison Frog. J. Am. Chem. Soc. 1992, 114, 3475-3478.
2. Qian, C.; Li, T.; Shen, T. Y.; Libertine-Garahan, L.; Eckman, J.; Biftu, T.; Ip, S. Epibatidine Is a Nicotinic Analgesic. Eur. J. Pharmacol. 1993, 250, R13-R14.
3. Badio, B.; Daly, J. W. Epibatidine, a Potent Analgetic and Nicotinic Agonist. Mol. Pharmacol. 1994, 45, 563-569.
4. Sullivan, J. P.; Bannon, A. W. Epibatidine: Pharmacological Properties of a Novel Nicotinic Acetycholine Receptor Agonist and Analgesic Agent. CNS Drug Rev. 1996, 2, 21-39.
5. Khan, I. M.; Youngblood, K. L.; Printz, M. P.; Yaksh, T. L.; Taylor, P. Spinal Nicotinic Receptor Expression in Spontane-ously Hypertensive Rats. Hypertension 1996, 28, 1093-1099.
6. Khan, I. M.; Marsala, M.; Printz, M. P.; Taylor, P.; Yaksh, T. L. Intrathecal Nicotinic Agonist-Elicited Release of Excitatory Amino Acids as Measured by In Vivo Spinal Microdialysis in Rats. J. Pharmacol. Exp. Ther. 1996, 278, 97-106.
7. Sullivan, J. P.; Decker, M. W.; Brioni, J. D.; Donnelly-Roberts, D.; Ander son, D. J.; Bannon, A. W.; Kang, C.-H.; Adams, P.; Piattoni-Kaplan, M.; Buckley, M.; Gopalakrishnan, M.; Williams, M.; Arneric, S. P. (±)-Epibatidine Elicits a Diversity of In Vitro and In Vivo Effects Mediated by Nicotinic Acetylcholine Receptors. J. Pharmacol. Exp. Ther. 1994, 272, 624-631.
8. Bonhaus, D. W.; Bley, K. R.; Broka, C. A.; Fontana, D. J.; Leung, E.; Lewis, R.; Shieh, A.; Wong, E. H. F. Characterization of the Electrophysiological, Biochemical and Behavioral Actions of Epibatidine. J. Pharmacol. Exp. Ther. 1995, 273, 1199-1203.
9. Rao, T. S.; Correa, L. D.; Reid, R. T.; Lloyd, G. K. Evaluation of Anti-nociceptive Effects of Neuronal Nicotinic Acetylcholine Receptor (NAChR) Ligands in the Rat Tail-Flick Assay. Neuropharmacology 1996, 35, 393-405.
10. Holladay, M. W.; Lebold, S. A.; Lin, N.-H. Structure-Activity Relationships of Nicotinic Acetylcholine Receptor Agonists as Potential Treatments for Dementia. Drug Dev. Res. 1995, 35, 191-213.
11. Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Brioni, J. D.; Radek, R. J.; McKenna, D. G.; Campbell, J. E.; Arneric, S. P.; Decker, M. W.; Bannon, A. W. (±)-Epibatidine Can Differentially Evoke Responses Mediated by Putative Subtypes of Nicotinic Acetylcholine Receptors (nAChRs). Med. Chem. Res. 1994, 4, 502-516.
12. Badio, B.; Shi, D.; Garraffo, M.; Daly, J. W. Antinociceptive Effects of the Alkaloid Epibatidine: Further Studies on Involvement of Nicotinic Receptors. Drug Dev. Res. 1995, 36, 46-59.
13. Khan, I. M.; Taylor, P.; Yaksh, T. L. Stimulatory Pathways and Sites of Action of Intrathecally Administered Nicotinic Agents, J. Pharmacol. Exp. Ther. 1994, 27, 1550-1557.
14. Abreo, M. A.; Lin, N.-H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A.-M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly- Roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-Pyridyl Ethers With Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors. J. Med. Chem. 1996, 39, 817-825.
15. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A.-M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-Azetidinylmethoxy)Pyridine]: In Vitro Pharmacological Properties of a Novel, High Affinity α4β2 Nicotinic Acetylcholine Receptor Ligand. Neuropharmacology 1996, 35, 725-734.
16. Effenberger, F.; Krebs, A.; Willrett, P. Zum Mechanismus der Carbodesilylierung 4-bzw. 5-substituierter 2-(Trimethylsily)pyridine mit Benzaldehyd. (On the Mechanism of Carbodesilylation of 4- and 5-Substituted 2-(Trimethylsilyl)-pyridine with Benzaldehyde.) Chem. Ber. 1992, 125, 1131-1140.
17. Abbreviations are as defined in J. Org. Chem. 1996, 61, 22A, unless otherwise noted.
18. 3H]Cytisine Binding to Nicotinic Cholinergic Receptors in Brain. Mol. Pharmacol. 1990, 39, 9-12.
19. McBride, P. E. The Health Consequences of Smoking. Med. Clin. N. Am. 1992, 76, 333-353.
20. Carlson, G. M.; Ruddon, R. W.; Hug, C. C., Jr.; Schmiege, S. K.; Bass, P. Analysis of the Site of Nicotine Action on Gastric Antrat and Duodenal Contractile Activity. J. Pharmacol. Exp. Ther. 1970, 773, 377-383.
21. Lukas, R. J. Expression of Ganglia-Type Nicotinic Acetylcholine Receptors and Nicotinic Binding Sites by Cells of the IMR-32 Human Neuroblastoma Clonal Line. J. Pharmacol. Exp. Ther. 1993, 265, 294-302.
22. Gopalakrishnan, M.; Monteggia, L. M.; Anderson, D. J.; Molinari, E. J.; Piattoni-Kaplan, M.; Donnelly-Roberts, D.; Arneric, S. P.; Sullivan, J. P. Stable Expression, Pharmacologic Properties and Regulation of the Human Neuronal Nicotinic cuft Receptor. J. Pharmacol. Exp. Ther. 1996, 276, 289-297.
23. Luther, M. A.; Schoepfer, R.; Whiting, P.; Casey, B.; Blatt, Y.; Montal, M. S.; Montal, M.; Lindstrom, J. A Muscle Acetylcholine Receptor is Expressed in the Human Cerebellar Medulloblastoma Cell Line TE671. J. Neurosci. 1989, 9, 1082-1095.
24. 3H]nicotine Binding to Putative High Affinity Receptor Sites in Rat Brain. Mol Pharmacol. 1987, 31, 392- 400.
25. Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Broad-Spectrum Non-Opioid Analgesic Activity of Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors. Science 1998, 279, 77-81.
26. Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Anderson, D. J.; Campbell, J. E.; Piattoni-Kaplan, M.; McKenna, D. G.; Wasicak, J. T.; Holladay, M. H.; Williams, M.; Arneric, S. P. ABT-594. I. In Vitro Profile of a Novel Analgesic Neuronal Nicotinic Acetylcholine Receptor (nAChR) Ligand. J. Pharmacol. Exp. Ther. 1998, in press.
27. Bannon, A. W.; Decker, M. W.; Curzon, P.; Buckley, M. J.; Kim, D. J. B.; Lynch, J. K.; Wasicak, J. T.; Arnold, W. H.; Holladay, M. W.; Arneric, S. P. 5-((2R)-Azetidinylmethoxy)-2-chloropyridine [ABT-594]: A Novel, Orally Effective Antinociceptive Agent Acting via Nicotinic Acetylcholine Receptors. II. In Vivo Characterization. J. Pharmacol. Exp. Ther. 1998, in press.
28. Decker, M. W.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Holladay, M. W.; Ryther, K. B.; Lin, N.-H.; Wasicak, J. T.; Williams, M.; Arneric, S. P. Antinociceptive Effects of the Novel Neuronal Nicotinic Acetylcholine Receptor Agonist, ABT-594, in Mice. Eur. J. Pharmacol. 1998, in press.
29. Lin, N.-H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodhgues, A. D.; Marsh, K. G.; Anderson, D. J.; Buccafusco, J. J.; Pendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Structure-Activity Studies on ABT-089: An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor (nAChR) Ligand with Cognition Enhancing Properties. J. Med. Chem. 1997, 40, 385-390.
30. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Gopalakrishnan, M.; Hu, I.; Campbell, J. E.; Anderson, D. J.; PiattoniKaplan, M.; Molinari, E.; McKenna, D. G.; Gunn, D. E.; Lin, N.H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Williams, M.; Arneric, S. P. ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]; A Potent and Selective Cholinergic Channel Modulator with Cytoprotective Properties. J. Pharmacol. Exp. Ther. 1997, 283, 235-246.
31. Briggs, C. A.; McKenna, D. G.; Piattoni-Kaplan, M. Human α7 Nicotinic Acetylcholine Receptor Responses to Novel Ligands. Neuropharmacology 1995, 34, 583-590.